Biotech "Tweets of the Week"
Bloodied but not beaten biotechs
(February 22-26, 2016)
Featuring:
$AMGN $BLUE $BMRN $CARA $CMRX $EDIT $GWPH $HRTX $MNKD $ONTY $PPHM $PTCT $RLYP $SRPT $TRVN $TTPH $VRX $XLRN
$XBI $IBB $LABU
FDA RTF #PrecisionMedicine
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
FDA Refuses to File PTC's DMD Application $PTCT
WTF... another RTF $PTCT Receives Refuse to File Letter from FDA for Translarna™ (ataluren) https://t.co/mek2c6ahI2
— Joe (@GantosJ) February 23, 2016
@JohnCFierce Ataluren failed in every pivotal study conducted by $PTCT, yet in the biotech bubble, it was given legit shot at success.
— Adam Feuerstein (@adamfeuerstein) February 23, 2016
gotta hand it to $PTCT CEO stuart peltz for blowing out of his shares a year ago at $70, great trade
— Brometheus (@biotechvalue) February 23, 2016
@Mykalt45 Credit Suisse and JPM had $Ptct as top pick, meanwhile CEO sold at $75. Sell Side Conflict of Interest, never more apparent.
— Dr. Paul DeSantis (@DrPaulyDeSantis) February 23, 2016
And $PTCT closes down 61%
— John Carroll (@JohnCFierce) February 23, 2016
$PTCT mgnt believe all they had to do is just conduct a study (even a failed one) re. EMA full approval... Really??? pic.twitter.com/Zu8qXiBGVn
— Andy Biotech (@AndyBiotech) February 24, 2016
@AndyBiotech fool one, fool twice in this market ? No chance $PTCT
— Raj R (@rajramaswamy) February 24, 2016
PTC Therapeutics's outperform rating reiterated at Cowen and Company. $120.00 PT. https://t.co/nqVFgT7h2l $PTCT #PTCT
— US Consumer News (@ConsumerFeed) February 24, 2016
EXCLUSIVE: Sanofi In Talks To Buy PTC Therapeutics $PTCT $SNY https://t.co/kbEHcA7dQ3
— Benzinga.com (@Benzinga) February 25, 2016
@bradloncar Among all buyout rumors lately, this makes the least sense! Genzyme gave Ataluren back years ago, $SNY now want to follow $BMRN?
— JQ (@jq1234t) February 25, 2016
$PTCT -- Not to mention that $SNY/Genzyme has already lost more than $100M on ataluren and dumped it years ago... pic.twitter.com/N9GNUIteRB
— Andy Biotech (@AndyBiotech) February 25, 2016
Potpourri of Valeant headlines $VRX
CVS plans to restrict use of $vrx toe fungus drug Jublia- would be required to fail other drugs first
— Douglas Allan (@Dougallan1) February 22, 2016
@MaxNisen What took them so long? Toothbrush+white vinegar works as well as—or better than—Jublia. $VRX
— Roy Friedman (@DewDiligence) February 22, 2016
BREAKING: Valeant expected to restate earnings in wake of internal review, likely to concern sales of drugs to distributor Philidor - DJ
— CNBC Now (@CNBCnow) February 22, 2016
Valeant getting smoked after hours pic.twitter.com/yVREzddjdE
— Joseph Weisenthal (@TheStalwart) February 22, 2016
$VRX new 52 week lows after hours. This name is a disaster.
— avidresearch (@avidresearch) February 22, 2016
DJ Valeant: About $58M of Net Revenue Recognized in 2H14 Shouldn't Have Been Recognized Upon Delivery of Product to Philidor $VRX
— zach (@zbiotech) February 23, 2016
$VRX said to schedule non-deal roadshow Feb. 29 between 2pm-3:30pm at UBS in NYC https://t.co/upCIw0B4BN
— Sasha Damouni Ellis (@SashaDamouni) February 24, 2016
NEW: $VRX CEO Pearson's health improving & is ready to return, but board debating whether Pearson should return – source (via @davidfaber)
— CNBC Now (@CNBCnow) February 25, 2016
Reaction to Relypsa's Veltassa commercial launch $RLYP
Bought a bit of $RLYP. Do they mail me the Pom Poms or do I have to go buy them somewhere?
— Mugatu Capital (@mugatushair) February 22, 2016
Bio-Twitter explodes with release of initial Veltassa scrip data. $RLYP
— Adam Feuerstein (@adamfeuerstein) February 24, 2016
$RLYP raised $44.2M via its ATM in Jan and Feb.
— PropThink (@PropThinker) February 24, 2016
. @cycleflyer @shaneblackmon $RLYP longs didn’t. And of course, bears are setting unrealistic expectations. That’s the current game.
— Adam Feuerstein (@adamfeuerstein) February 24, 2016
$RLYP No way MS-BERENS does not come out&lower his target even more to 6-7.For those wanting to add that might be TIME.REVERSAL on it???
— dough (@tgtxdough) February 24, 2016
$RLYP PR mentioned that "agreements have been signed w/ $ESRX and $CVS". Will be interesting to get more details on the call.
— Andy Biotech (@AndyBiotech) February 24, 2016
Regardless of $RLYP outcome, because I am happy to flip to short, I will be tweeting as both crazy bull and crazy bear biotweep today.
— Mugatu Capital (@mugatushair) February 24, 2016
@princetongb add: market sucks
— Stan D'Andrea (@stanleydandrea) February 24, 2016
Very bold or stupid to guide opex > your cash balance in this market $RLYP
— chillipickle (@chillipickle7) February 24, 2016
@DrSManian selloff related to ATM being hit and obnoxious operational spend by execs. not a good trend after launch of drug. $RLYP
— PlungeProtectionTeam (@plungeprotect) February 25, 2016
Look pretty smart selling out of $RLYP today huh?!
— Michael Torres, PhD (@Mykalt45) February 25, 2016
P.S., I bought EOD! Fool! Like I said. Losing trades have been all about fundamentals.
so after ~5 prior attempts, it appears berens spin this go-around on his $RLYP 'roulette wheel of death' landed on 'time to profitability'
— zach (@zbiotech) February 25, 2016
Monthly rx numbers will provide a good insight into how launch of $rlyp is underway. Imno still believe over reaction here to atm
— Pharm. D (@Pharmdca) February 25, 2016
@Sharma1981N @hydrogenblimp @Sport234a The company probably like many others thought it could raise money via public offering around #JPM16
— JQ (@jq1234t) February 25, 2016
It's really not about if $RLYP had a successful launch. It's easier and more profitable in small biotech to go short! End of story for today
— HumbleBioTrader (@HumbleBioTrader) February 25, 2016
$rlyp shorts not throwing in the towel yet, in fact wouldn't be surprised if they sold more on this bump this morning. More pain to come.
— Pawcio (@pawcio2009) February 25, 2016
...Just in from Washington, DC
Senate voted 89-4 to confirm Dr. Robert Califf as next FDA commissionerhttps://t.co/z4g62DxQsA
— Andy Biotech (@AndyBiotech) February 24, 2016
Congrats @calif001! pic.twitter.com/17aRFpbek7
Obama: Our "health care system is [often] a disease-care system."
— Dan Diamond (@ddiamond) February 25, 2016
"If we do #PrecisionMedicine right, it's going to save a lot of lives."
"Who owns the data? I'd like to think if someone does a test on me, and my genes, that's mine," Obama says to applause. #PrecisionMedicine
— Dan Diamond (@ddiamond) February 25, 2016
Obama: We must update health care's "regulatory framework, which was designed for another era of medicine." #PrecisionMedicine
— Dan Diamond (@ddiamond) February 25, 2016
Obama: #PrecisionMedicine isn't far away.
— Dan Diamond (@ddiamond) February 25, 2016
"I'm confident that for Malia and Sasha's generation, they'll be able to live healthier lives."
Obama Is Using The Bully Pulpit To Set Patient Data Free via @forbes https://t.co/NbdXE50tuL
— Matthew Herper (@matthewherper) February 25, 2016
Here is fact sheet for the #PrecisionMedicine initiative w/ "details" on efforts by dozens of companies/institutions https://t.co/9UCkxGGO6K
— Andrew G. (@BioDueDiligence) February 25, 2016
As seen on the stream
This sheet shows the price at which #biotech companies did their last follow-on equity raise. Warning: it’s brutal. https://t.co/TfvE0NjIYM
— Brad Loncar (@bradloncar) February 20, 2016
@ACInvestorBlog didn’t seem encouraging 4 $cmrx, unfortunately. Canceling P3 kidney trials, no activity vs BK virus. Back to drawing board.
— Michael Levy (@mjlevy76) February 21, 2016
$TRVN spox tells me oliceridine is the first pain drug to receive FDA’s Breakthrough Therapy Designation.
— Adam Feuerstein (@adamfeuerstein) February 22, 2016
How to do the #JPM16 hustle: (aka my longish read on those few days in SF & the climate for young biotechs): https://t.co/Vhz5rnyqD3
— Lisa Jarvis (@lisamjarvis) February 22, 2016
$OMED 9.48
— Tom Wrigley (@WrigleyTom) February 22, 2016
OncoMed Presents Updated Phase 1b Data
for Tarextumab in Small Cell Lung Cancerhttps://t.co/sbrMA7haar
@AndyBiotech This is a big miss. Hip fractures are by far the most important clinically.
— NSharma (@Sharma1981N) February 22, 2016
Brent Saunders says not expecting drug-pricing "rhetoric" to affect $AGN operations.
— Charley Grant (@CGrantWSJ) February 22, 2016
$EYES pop on chatter will be feat on VICE episode
— The Daytrade™ (@d4ytrad3) February 22, 2016
@FajaJake Quite a large group of similar bios over the last year $ZFGN $CLVS $ESPR $TTPH etc. Haircut club?
— Tony Friedman (@zzlangerhans) February 22, 2016
Sold 1/4 $EDIT position for 60% gain. Forgot how good that feels!
— 23Chromz (@23Chromz) February 22, 2016
Kudos to $PFE for publishing archived pipeline PDFs: https://t.co/YEwEL3FfYK Since the rest don't, BDD does for you: https://t.co/jJks3oVQFW
— Andrew G. (@BioDueDiligence) February 22, 2016
$TTPH to report “earnings” after the bell tomorrow (4:30 ET). Expect update regarding FDA discussions on filing with existing P3 data
— Dan Smithey (@dan_smithey) February 22, 2016
$SGEN Baker Bros raise stake to 28.4%
— Bio Stocks™ (@BioStocks) February 22, 2016
Should we tell the presidential candidates that prescription drug spending growth slowed way down in 2015?
— Brad Loncar (@bradloncar) February 23, 2016
Big congrats to @AKAarsalan for the new https://t.co/iTVcbVrDjZ site. I love it. You should check it out.
— John Carroll (@JohnCFierce) February 23, 2016
RTF ... CRL ... people learning about a lot of new letters over the last couple months. What happened to the FDA that approved everything?
— Tyler (@TylerHCanalyst) February 23, 2016
#AACR16 abstract titles outhttps://t.co/ExOVlJVZXh
— Andy Biotech (@AndyBiotech) February 23, 2016
$HRTX..$18.15 now from $19.80 yesterday. Looking attractive again!
— Sheff (@SheffStation) February 23, 2016
$CPXX & $PETX have held up well today. $CPXX hit low of $2 before racing back. $IBB $XBI getting hammered here.
— Sheff (@SheffStation) February 23, 2016
$TTPH no update/color yet from the FDA, still expected tho in Q1'16
— zach (@zbiotech) February 23, 2016
@bio_clouseau Really? Hope they aren't as sloppy with upcoming 2nd interim analysis of ACT IV.
— JQ (@jq1234t) February 23, 2016
I'm at an awards show for ETFs (yes, that exists) and $IBB won for best long-term ETF. Here were the nominees: pic.twitter.com/B3KexPAmXb
— Brad Loncar (@bradloncar) February 24, 2016
$ICPT PT lowered to $275 from $340 at Citi
— Bio Stocks™ (@BioStocks) February 24, 2016
$ITEK Announces Poster Presentation at the American Glaucoma Society’s 2016 Annual Meeting on March 4 https://t.co/kO6N49Zk3s
— Helen Ong (@Lin_ling_88) February 24, 2016
$ONTY Can someone explain this extremely overdone selloff? ...I'm perplexed
— BioBreakout (@BioBreakout) February 24, 2016
@adamfeuerstein drugs are less likely to work when the market thinks they won't
— zach (@zbiotech) February 24, 2016
$SRPT progressive diseases r tricky. Rather have data for n=12 for 4 years than n=48 for 1 year. Long term followup is where signal emerges
— avidresearch (@avidresearch) February 24, 2016
Right now $LABU is flattish, but high to low it's traded within a 16% range today. $XBI $IBB
— 23aloha (@23aloha) February 24, 2016
Almost feels like we have moved from the STFR to BTFD again already... $STUDY
— Jean Fonteneau (@JFinDallas) February 24, 2016
What's changed in public oncology investing: we r investing in much earlier-stage proj. AACR is the new ASCO! @bradloncar on my NYC panel
— Steven Dickman (@cbtadvisors) February 24, 2016
So sad to hear about the loss of Kerri Mowen and now Holbrook Kohrt. A tragic week for immunology.
— Mark (ツ) (@Mark_Cobbold) February 24, 2016
@Bucktweet_Say @Mykalt45 @sfef84 @McEuen we probably all have our "never again will I invest in Biotech moment" I sure do.
— BioBounce.com (@BioBounce) February 25, 2016
Daiichi Sankyo starts exon 45 targetting DMD trial $SRPT $BMRN https://t.co/qA8wUQx3p0
— j l (@bio_clouseau) February 25, 2016
Citi Robyn K. initiated new biotech coverage last night.
— Adam Feuerstein (@adamfeuerstein) February 25, 2016
Buys: $ADAP, $GILD, $JUNO, $KITE, $REGN, $BIIB, $CELG
Neutrals: $AMGN, $BLCM, $ALXN
Daiichi Sankyo starts exon 45 targetting DMD trial $SRPT $BMRN https://t.co/qA8wUQx3p0
— j l (@bio_clouseau) February 25, 2016
prob w/neratinib is QOL risk/benefit in given pt population...so a similar MOA/cleaner drug in a more unmet need pt population is... $ONTY
— zach (@zbiotech) February 25, 2016
More details emerge on the French clinical trial disaster: https://t.co/ThjdvSOO9s
— Derek Lowe (@Dereklowe) February 25, 2016
@adamsinger Cool. I’m out of pocket so haven’t been able to check out this morning’s update, but doesn’t seem right for it to be down 8%.
— Brad Loncar (@bradloncar) February 25, 2016
$XLRN is down because co said they’ll need a full ph3 for dalantercept after the DART study.
— Brad Loncar (@bradloncar) February 25, 2016
$GWPH cancelled presentation at Cowen conf. sked for March 7-9. Reason: Abundance of caution ahead of epidiolex ph3 data release.
— Adam Feuerstein (@adamfeuerstein) February 25, 2016
On $GWPH -- Avoiding investor conferences, 1x1 mtgs w/ investors while crucial epidiolex data hang in air is smart, responsible decision.
— Adam Feuerstein (@adamfeuerstein) February 25, 2016
$CARA '845 on clinical hold
— zach (@zbiotech) February 25, 2016
$BLUE CFO leaving
— zach (@zbiotech) February 25, 2016
$PPHM discontinues bavituximab Ph3 trial in NSCLC. But of course that doesn't "diminishes enthusiasm for advancing I/O combo trials"...
— Andy Biotech (@AndyBiotech) February 25, 2016
$SNTA and $PPHM have gone down in flames so far, just waiting on $OGXI still...
— Andrew G. (@BioDueDiligence) February 25, 2016
hate to say it but biotwitter stk picking has been horrible: $RLYP $SRPT $BLUE $ESPR $TGTX to name a few
— lucas aspen (@riverstonecap) February 24, 2016
U.S.-BASED HEALTHCARE/BIOTECH SECTOR FUNDS POST $331 MLN OUTFLOW; NINTH STRAIGHT WEEK OF OUTFLOWS -LIPPER
— Douglas Allan (@Dougallan1) February 25, 2016
The most important sector for human future - biotech/healthcare - is seeing unprecedented fund outflows, but the tv guy is bullish on pizza.
— David Maizenberg (@biologypartners) February 25, 2016
#Biotech Short % Float$INSY 80%$MNKD 47$TKAI 45$ESPR 39$PTCT 34$RLYP 34$ZIOP 33$EGRX 33$TSRO 33$INVA 32$SRPT 31$MYGN 31$BIOS 30
— Biotech 5 (@Biotech_5) February 25, 2016
Al Mann, 90, is dead. $MNKD was an anomaly in a hugely successful career as businessman, generous philanthropist. Peace to his family.
— Adam Feuerstein (@adamfeuerstein) February 26, 2016
RIP Al Mann $MNKD https://t.co/z5pXAsaVuU
— Red Acre Investments (@redacre) February 26, 2016
$ESPR JMP PT $113
— Odi (@odibro) February 26, 2016
Chardan PT $13.... Did Chardan forget the 1?
We'll see!
$IONS This proves again that pipeline quantity doesn't really matter in biotech, all you need is just one good drug: $VRUS $PCYC $ITMN $RCPT
— Andy Biotech (@AndyBiotech) February 26, 2016
Best performing bios YTD per my Schwab screen: $NNVC +128%, $HEB +105%, $ATHX +90%, $MNOV +81%, $BITI +72%, $CVM +62%. What a set of names
— Daniel Ward (@danwardbio) February 26, 2016
Where are all those $PPHM trolls who gave me such a hard time over bavituximab? Phase 3 failure in lung cancer should not be a surprise
— Sally Church (@MaverickNY) February 26, 2016
$EDIT Editas joins $1 billion market cap club today, first public preclinical biotech co ever reaches that? pic.twitter.com/e4HZjPq7yp
— Andy Biotech (@AndyBiotech) February 26, 2016
CRISPR & blind skiing: Personal, thoughtful, well-written piece on gene editing by @ethanjweiss: https://t.co/gQ8qzMMIf5
— Frank David (@Frank_S_David) February 24, 2016